This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

About JANUVIA® (sitagliptin)

JANUVIA is a once daily DPP-4 inhibitor for the treatment of type 2 diabetes (T2DM) in adults. JANUVIA is often prescribed in combination with metformin when diet and exercise plus metformin is not achieving the glycaemic control that people need.1

With a wide range of indications in T2DM, JANUVIA is suitable for adults with T2DM in:1



JANUVIA
Monotherapy (oral) If metformin is contraindicated or not tolerated
Dual therapy (oral) Add on to metformin
Add on to SU
Add on to TZD
Triple therapy (oral) Add on to metformin + SU
Add on to metformin + TZD

How does JANUVIA help people with T2DM?

People can feel concerned about their diabetes progressing to a new stage.2

If they are uncontrolled on metformin and you are considering prescribing a DPP-4 inhibitor, JANUVIA offers proven efficacy in HbA1c reductions,3 long-term maintenance4 and an established safety profile.5

JANUVIA effectively reduces blood glucose with metformin3

When a person with T2DM is struggling to reach their target HbA1c levels, it can be worrying for both them and their healthcare provider.

In combination with metformin, JANUVIA has been shown to help people reduce their HbA1c levels. After a year of treatment, JANUVIA plus metformin showed similar reductions in blood glucose to a SU plus metformin, in people from a varied HbA1c baseline.3

Dosing

JANUVIA 100 mg is suitable for 91% of people with T2DM1,6,7

Dose reductions for JANUVIA are in line with NICE recommendations for metformin1,6,7

GFR (ml/min) >45 >30 to <45 <30
JANUVIA (daily dose)

100 mg

Continue

91%

50 mg 25 mg
Metformin Review Stop
Patients with T2DM and eGFR >45/min/1.732 (%) 9%

Please consult the SPC for contraindictations, warnings and precautions against the use of JANUVIA.1

Like what you're seeing?


Register now

Why JANUVIA?

Reducing HbA1c levels

HbA1c reductions observed at week 52 in all patients, including >65 year olds3

Graph showing HbA1c reductions observed at week 52 in all patients, including >65 year olds Graph showing HbA1c reductions observed at week 52 in all patients, including >65 year olds Graph showing HbA1c reductions observed at week 52 in all patients, including >65 year olds Graph showing HbA1c reductions observed at week 52 in all patients, including >65 year olds Graph showing HbA1c reductions observed at week 52 in all patients, including >65 year olds Graph showing HbA1c reductions observed at week 52 in all patients, including >65 year olds

* Per protocol population

Adapted from Nauck et al, 2007 3

NICE suggest patients should aim to achieve a 0.5% reduction6


Study design

JANUVIA effectively reduces blood glucose.8

Helping your people over 65 years old to gain better control of their blood glucose is a priority of diabetes treatment.8

In older people JANUVIA reduces HbA1c by 0.5% compared to placebo,8 in line with NICE recommendations.6

Change in HbA1c over 24 weeks8

Graph showing n older people JANUVIA reduces HbA1c by 0.5% compared to placebo, in line with NICE recommendations. Graph showing n older people JANUVIA reduces HbA1c by 0.5% compared to placebo, in line with NICE recommendations.
Adapted from Barzilai N et al. 20118
* p<0.001 for between-group comparsions of LS-mean at timepoints for which inference testing was prespecified.8
Study design

Recent study CompoSIT-M has shown how early initiation of JANUVIA during metformin up-titration can help your patients.9


Find out more

Treatment control

JANUVIA offers longer control of HbA1c than an SU4

A real world study found that people treated with JANUVIA plus metformin maintained their treatment without modification* for significantly longer than those using an SU plus metformin.4

Graph showing median time of treatment maintenance for JANUVIA plus metformin compared with SU plus metformin Graph showing median time of treatment maintenance for JANUVIA plus metformin compared with SU plus metformin

*The main reason for treatment modification in both groups was insufficient efficacy. Treatment modification was defined as any discontinuation of a drug or addition of, or switch to, a new drug. Changes in dose were not considered a treatment modification4

Adapted from Valensi et al, 2015

Study design

Recent study CompoSIT-I has shown how treatment with JANUVIA during insulin therapy can benefit your patients with T2DM.10


Find out more

CV and renal safety

JANUVIA offer people aged 65 and over with T2DM the reassurance of an established renal and CV safety profile5

Many older people with T2DM may experience renal damage that can lead to increased cardiovascular risk.5 TECOS explored the safety of JANUVIA in the longest CV safety trial of DPP-4 inhibitors in T2DM to date vs. usual care alone.5

Key trial design details:

- Randomised double blind CV safety trial5

- Over 14,000 patients5

- 3 years median follow up5

When added to usual care, JANUVIA demonstrated:

No increased CV risk5

Primary composite endpoint of CV death, nonfatal MI, nonfatal stroke, nonfatal myocardial infarction, or hospitalisation for unstable angina (PP HR 0.98 (95% CI: 0.88-1.09), p<0.001 for non-inferiority vs. placebo, n=14,523)5

No increased risk of hospitalisation for heart failure5 (secondary endpoint)

ITT HR 1.00 (95% CI: 0.83-1.20), p=0.985
PP: per protocol; HR: hazard ratio; CI: confidence interval; ITT: intention-to-treat-population.

Study design

Related content

 

References

  1. JANUVIA Summary of Product Characteristics.
  2. Quandt SA et al. J Appl Gerontol. 2013;32(7):783-803.
  3. Nauck MA et al. Diabetes Obes Metab. 2007;9(2):194-205.
  4. Valensi P et al. Diabetes Metab. 2015;41(3)231-238.
  5. Green JB et al. N Engl J Med. 2015;373(3):232–242.
  6. National Institute for Health and Clinical Excellence (NICE): Type 2 diabetes in adults management. NICE Guideline 28. August 2019.
  7. Bailey RA et al. BMC Res Notes. 2014;7:415
  8. Barzilai N et al. Curr Med Res Opin. 2011;27:1049–1058.
  9. Frias JP., et al. Diabetes Obes Metab. 2019 May;21(5):1128-1135
  10. Roussel R., et al. Diabetes Obes Metab. 2018;1–10

GB-DIA-00682 | Date of Preparation: January 2020